Investigational drugs for head and neck cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Urban D, Corry J, Rischin D, et al. What is the best treatment for patients with human papillomavirus–positive and –negative oropharyngeal cancer? Cancer. 2014;120:1462–1470.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Rampias T, Vermorken JB, The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2014;25:2101–2115.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578.
   PubMed Web of Science ®Google Scholar
• Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–1162.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Frederick MJ, Pickerin CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–1157.
   PubMed Web of Science ®Google Scholar
• Ugurluer G, Ozsahin M. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. Expert Opin Investig Drugs. 2014;23:1637–1654.
   PubMed Web of Science ®Google Scholar
• Sheppard K, Kinross KM, Solomon B, et al. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 2012;17:69–95.
   PubMedGoogle Scholar
• Riaz N, Morris LG, Lee W, et al. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis. 2014;1:75–86.
   PubMedGoogle Scholar
• Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761–769.
   PubMed Web of Science ®Google Scholar
• Kozaki K-I, Imoto I, Pimkhaokham A, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Science. 2006;97:1351–1358.
   PubMed Web of Science ®Google Scholar
• Estilo CL, O-charoenrat P, Ngai I, et al. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res. 2003;9:2300–2306.
   PubMed Web of Science ®Google Scholar
• Rebucci M, Peixoto P, Dewitte A, et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol. 2011;38:189–200.
   PubMed Web of Science ®Google Scholar
• Lechner M, Frampton GM, Fenton T, et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med. 2013;5:49.
   PubMed Web of Science ®Google Scholar
• Hayes DN, Van Waes C, Seiwert TY. Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J Clin Oncol. 2015;33:3227–3234.
   PubMed Web of Science ®Google Scholar
• Velho PH, Castro G, Chung CH. Targeting the PI3K pathway in head and neck squamous cell carcinoma. Am Soc Clin Oncol Educ Book. 2015;35:123–128.
   Google Scholar
• Jimeno A, Shirai K, Choi M, et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol. 2015;26:556–561.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Bauman JE, Weissman C, et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol. 2015;51:383–388.
   PubMed Web of Science ®Google Scholar
• Kim HR, Kang HN, Yun MR, et al. Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). J Clin Oncol. 2015;33(suppl):abstr 6049.
   Google Scholar
• Razak ARA, Ahn M, Yen C, et al. Phase lB/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2014;32(5 Suppl):6044.
   Web of Science ®Google Scholar
• Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006;5:766–770.
   PubMed Web of Science ®Google Scholar
• Fury MG, Lee NY, Sherman E, et al. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013;87:479–486.
   PubMed Web of Science ®Google Scholar
• Fury MG, Sherman E, Ho AL, et al. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 2013;119:1823–1831.
   PubMed Web of Science ®Google Scholar
• Varadarajan P, Panayotis Kotsakis A, Martin A, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2012;30(suppl):abstr 5541.
   Google Scholar
• Massarelli E, Lin H, Ginsberg LE, et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015;26:1476–1480.
   PubMed Web of Science ®Google Scholar
• Saba NF, Hurwitz SJ, Magliocca K, et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014;120:3940–3951.
   PubMed Web of Science ®Google Scholar
• Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24:3089–3094.
   PubMed Web of Science ®Google Scholar
• Kim D-W, Oh D-Y, Shin SH, et al. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer. 2014;14:795.
   PubMed Web of Science ®Google Scholar
• Fury MG, Sherman E, Ho A, et al. A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol. 2012;70:121–128.
   PubMed Web of Science ®Google Scholar
• Grünwald V, Keilholz U, Boehm A, et al. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann Oncol. 2015;26:561–567.
   PubMed Web of Science ®Google Scholar
• Bauman JE, Arias-Pulido H, Lee S-J, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013;49:461–467.
   PubMed Web of Science ®Google Scholar
• Wang Z, Martin D, Molinolo AA, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst. 2014;106(9).
   Google Scholar
• Bowles DW, Diamond JR, Lam ET, et al. Phase I study of oral Rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014;20:1656–1665.
   PubMed Web of Science ®Google Scholar
• Burtness B, Baumann JE, Galloway T, Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR-inhibition. Lancet Oncol. 2013;14:e302–e309.
   PubMed Web of Science ®Google Scholar
• Blumenshein GR Jr, Millis GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-CMET axis in cancer therapy. J Clin Oncol. 2012;30:3287–3296.
   PubMed Web of Science ®Google Scholar
• Seiwert T, Sarantopoulos J, Kallender H, et al. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013;31:417–424.
   PubMed Web of Science ®Google Scholar
• Hong DS, Rosen P, Lockhart AC, et al. A first-in-human study of AMG-208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015;6:18693–18706.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Hong DS, Burris HA III, et al. Phase I, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74:125–130.
   PubMed Web of Science ®Google Scholar
• Wong AL, Soo RA, Tan DS, et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT)3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015;26:998–1005.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Worden FP, Adkins D, et al. A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer. J Clin Oncol. 2015;33(suppl):abstr 6060.
   Google Scholar
• Bang YJ, Su WC, Nam DH, et al. Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. J Clin Oncol. 2014;32:5s (suppl; abstr 2520).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger CK, Sharma S, Shapiro G, et al. Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors. J Clin Oncol. 2015;33(suppl):abstr 2589.
   Google Scholar
• Xi W-H, Yang L-Y, Cao Z-Y, et al. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma. Biochem Biophys Res Comm. 2015;457:723–729.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Matsushima T, Kawano S. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci. 2014;105:723–730.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394.
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–3646.
   PubMed Web of Science ®Google Scholar
• Medova M, Aebersold DM, Zimmer Y. The molecular crosstalk between the MET receptor tyrosine kinase and the DNA damage response-biological and clinical aspects. Cancers. 2013;6:1–27.
   PubMedGoogle Scholar
• Poeta ML, Manola J, Goldwasser MA. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E, Histone deacetylases and cancer. Oncogene. 2007;26:5420–5432.
   PubMed Web of Science ®Google Scholar
• Giudice FS, Pinto DS Jr, Nor JE, et al. Inhibition of Histone deacetylase impacts cancer stem cells and induces epitelial-mesenchyme transition of head and neck cancer. PloS One. 2013;8:1–11.
   Web of Science ®Google Scholar
• Chikamatsu K, Ishii H, Murata T, et al. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Cancer Sci. 2013;104:1468–1475.
   PubMed Web of Science ®Google Scholar
• Prystowsky MB, Adomako A, Smith RV, et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol. 2009;218:467–477.
   PubMed Web of Science ®Google Scholar
• Eriksson I, Joosten M, Roberg K, et al. The histone deacetylase inhibitor trichostatin A reduces lyposomal pH and enhances cisplatin-induced apoptosis. Exp Cell Res. 2013;319:12–20.
   PubMed Web of Science ®Google Scholar
• Hehlgans S, Storch K, Lange I, et al. The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. Radiother Oncol. 2013;109:126–132.
   PubMed Web of Science ®Google Scholar
• Zang Y, Kirk CJ, Johnson DE, et al. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biol Ther. 2014;15:1142–1152.
   PubMed Web of Science ®Google Scholar
• Kim JK, Guan J, Chang I, et al. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther. 2010;9:1977–1984.
   PubMed Web of Science ®Google Scholar
• Stauber RH, Knauer SK, Habtemichael N, et al. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget. 2012;3:31–43.
   PubMed Web of Science ®Google Scholar
• Shim S-H, Lee C-T, Lee -J-J, et al. A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC. Tumor Biol. 2010;31:659–666.
   PubMed Web of Science ®Google Scholar
• Kothari V, Joshi G, Nama S, et al. HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int J Cancer. 2009;126:733–742.
   Web of Science ®Google Scholar
• Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 2011;226:2378–2390.
   PubMed Web of Science ®Google Scholar
• Chang -C-C, Lin B-R, Chen S-T, et al. HDAC2 promotes cell migration/invasion abilities through HIF-Iα stabilization in human oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:567–575.
   PubMed Web of Science ®Google Scholar
• Theocharis S, Klijanienko J, Giaginis C, et al. Histone deacetylase-I and −2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med. 2011;40:706–714.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Merrill SK, Vassiliki AP, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008;26:81–87.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13:3605–3610.
   PubMed Web of Science ®Google Scholar
• Haingentz M Jr, Kim M, Sarta C, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncology. 2012;48:1281–1288.
   PubMed Web of Science ®Google Scholar
• Chen EX, Winquist E, Ho C, et al. Vorinostat (VOR) and capecitabine (CAP) in recurrent and/or metastatic squamous cell carcinoma of head and neck (RMHNSCC): A study of the princess margaret phase ii consortium. J Clin Oncol. 2014;32(suppl):abstr e17001.
   Google Scholar
• Goncalves PH, Kummar S, Siu L, et al. A phase II study of suberoylanilide hydroxamic acid (SAHA) n subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC). J Clin Oncol. 2013;31(suppl):abstr 6045.
   Google Scholar
• Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001;61:5911–5918.
   PubMed Web of Science ®Google Scholar
• Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res. 2001;7:435–442.
   PubMed Web of Science ®Google Scholar
• Bian Y, Han J, Kannabiran V, et al. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer. Int J Biol Sci. 2015;11(4):411–422.
   PubMed Web of Science ®Google Scholar
• Mohan S, Vander Broek R, Shah S, et al. MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates antitumor effects in human head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:3946–3956.
   PubMed Web of Science ®Google Scholar
• Judd NP, Winkler AE, Murillo-Sauca O, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012;72:365–374.
   PubMed Web of Science ®Google Scholar
• Ma BB, Lui VW, Cheung CS, et al. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. Invest New Drugs. 2013;31:30–38.
   PubMed Web of Science ®Google Scholar
• Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007;67:4605–4619.
   PubMed Web of Science ®Google Scholar
• Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, et al The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016;273:801–809.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al; PALOMA3 study group. palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016; S1470–S2045. 00613-0.
   Google Scholar
• Michel LS, Ley JC, Wildes TM, et al. Phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2015;33:Abstr 6063.
   Google Scholar
• Perrone F, Bossi P, Cortelazzi B, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol. 2010;28:761–766.
   PubMed Web of Science ®Google Scholar
• Peltonen JK, Vähäkangas KH, Helppi HM, et al. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study. Head Neck Oncol. 2011;3:20.
   PubMedGoogle Scholar
• Osman AA, Neskey DM, Katsonis P, et al. Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Res. 2015;75:1205–1215.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Patel AA, Wang J, et al. Wee-1 kinase inhibition sensitizes high-risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins. Clin Cancer Res. 2015;21:4831–4844.
   PubMed Web of Science ®Google Scholar
• Osman AA, Monroe MM, Ortega Alves MV, et al. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther. 2015;14:608–619.
   PubMed Web of Science ®Google Scholar
• Do K, Wilsker D, Ji J. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015;33:3409–3415.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Braakenhoff RH, et al. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.
   PubMed Web of Science ®Google Scholar
• Ho AS, Kannan K, Roy DM. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791–798.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Davies HR, Mitani Y. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965–2968.
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Mitani Y, Cai Y, et al. Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival. J Clin Oncol. 2015;33(suppl):abstr 6081.
   Google Scholar
• Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014;40:390–404.
   PubMed Web of Science ®Google Scholar
• Yap LF, Lee D, Khairuddin A, et al. The opposing roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis. 2015;21:850–857.
   PubMed Web of Science ®Google Scholar
• Gu F, Ma Y, Zhang Z, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep. 2010;23:671–676.
   PubMed Web of Science ®Google Scholar
• Man C-H, Wei-Man Lun S, Wai-Ying Hui J, et al. Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. J Pathol. 2012;226:471–481.
   PubMed Web of Science ®Google Scholar
• Yu S, Zhang R, Liu F, et al. Down-regulation of Notch signaling by a γ-secretase inhibitor enhances the radiosensitivity of nasopharyngeal carcinoma cells. Oncol Rep. 2011;26:1323–1328.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Munster PN, Hollebecque A, et al. Results of a phase I trial combining ridaforolimus and MK-0752 in patients with advanced solid tumors. Eur J Cancer. 2015;51:1865–1873.
   PubMed Web of Science ®Google Scholar
• Ondrey FG, Dong G, Sunwoo J. Constitutive activation of transcription factors NF-(k)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express proinflammatory and pro-angiogenic cytokines. Mol Carcinog. 1999;26:119–129.
   PubMed Web of Science ®Google Scholar
• Kesarwala AH, Samrakandi MM, Piwnica-Worms D. Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. Cancer Res. 2009;69:976–983.
   PubMed Web of Science ®Google Scholar
• Argiris A, Duffy AG, Kummar S. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res. 2011;17:5755–5764.
   PubMed Web of Science ®Google Scholar
• Hui KF, Chiang AK. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism. Int J Cancer. 2014;135:2950–2961.
   PubMed Web of Science ®Google Scholar
• Hui KF, Lam BH, Ho DN, et al. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein–Barr virus. Mol Cancer Ther. 2013;12:747–758.
   PubMed Web of Science ®Google Scholar
• Zang Y, Thomas SM, Chan ET, et al. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012;8:1873–1874.
   PubMed Web of Science ®Google Scholar
• Han B, Yao W, Oh Y-T, et al. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget. 2015;6:17532–17542.
   PubMed Web of Science ®Google Scholar
• Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2010;21:864–870.
   PubMed Web of Science ®Google Scholar
• Bommakanti SV, Dudek AZ, Khatri A, et al. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. Am J Clin Oncol. 2011;34:597–602.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 2009;100:1379–1384.
   PubMed Web of Science ®Google Scholar
• Gilbert J, Lee JW, Argiris A, et al. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2013;35:942–948.
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Burtness B, et al. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011;117:3374–3382.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Chen C, Rabinovitch R, et al. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys. 2010;78:521–526.
   PubMed Web of Science ®Google Scholar
• Kubicek GJ, Axelrod RS, Machtay M, et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2012;83:1192–1197.
   PubMed Web of Science ®Google Scholar
• Ninan JA, Bailey H, Kolesar J, et al. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol. 2009;27:15s. (suppl; abstr 2531)
   Google Scholar
• Morris JC, Citrin DE, Nottingham L, et al. Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2010;28:15s. (suppl: abstr 2603)
   Google Scholar
• Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;63:1400–1412.
   PubMed Web of Science ®Google Scholar
• Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978;28:444–449.
   PubMed Web of Science ®Google Scholar
• Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332–1334.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010;16:3067–3077.
   PubMed Web of Science ®Google Scholar
• Comins C, Spicer J, Protheroe A, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010;16:5564–5572.
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Arkenau H-T, Harrington K, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011;17:581–588.
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Roulstone V, Twigger K, et al Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18:2080–2089.
   PubMed Web of Science ®Google Scholar
• Alexandrov L, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
   PubMed Web of Science ®Google Scholar
• Soo RA. Shedding light on the molecular determinants of response to anti-PD-1 therapy. Transl Lung Cancer Res. 2015;4:816–819.
   PubMedGoogle Scholar
• Lyford-Pike S, Peng S, Young GD, et al. Carcinoma resistance of HPV-associated head and neck squamous cell evidence for a role of the PD-1: PD-L1Pathway in Immune. Cancer Res. 2013;73:1733–1741.
   PubMed Web of Science ®Google Scholar
• Lalami Y, Awada A, Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev. 2016;43:113–123.
   PubMed Web of Science ®Google Scholar
• Allen CT, Clavijo PE, Van Waes C, et al. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel). 2015;7:2397–2414.
   PubMed Web of Science ®Google Scholar
• Chen Z, Seiwert TY, Haddad RI, et al., et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015;33(suppl):abstrLBA6008.
   Google Scholar
• Gillison M, Blumenschein G, Fayette J et al. Nivolumab (nivo) vs investigator’s choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. Abstract CT099, AACR Annual Meeting 2016.
   Google Scholar
• Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13:7086–7092.
   PubMed Web of Science ®Google Scholar
• Del Campo JM, Hitt R, Sebastian P, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2011;105:618–627.
   PubMed Web of Science ®Google Scholar
• Schmitz S, Hamoir M, Reychler H, et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24:2261–2266.
   PubMed Web of Science ®Google Scholar
• Chau NG, Li YY, Jo VY, et al. Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma. Clin Cancer Res. 2016. Epub ahead of print.
   Google Scholar